No Data
No Data
BOCOM Intl: Short-term pharmaceutical sector still has some room for recovery, focusing on recommending Simcere Pharma (02096) and others.
bocom intl key recommended simcere pharma (02096), hutchmed (china) (00013), connoah-b (02162) and akeso (09926), etc.
Announcement Highlights | new china life insurance: The net profit attributable to the mother is expected to increase by 95%-115% in the first three quarters; sunac: Sales in the first 9 months decreased by 48.68% year-on-year.
Wuxi Apptec: No decision has been made regarding the sale of its WuXi ATU business; Tencent: Spent 0.703 billion Hong Kong dollars to repurchase 1.56 million shares, repurchase price range is 438.6-474.8 Hong Kong dollars.
Simcere Pharma (02096) spent approximately 8.0849 million Hong Kong dollars to repurchase 1.175 million shares on October 3.
Simcere Pharma (02096) announced on October 3, 2024, to repurchase approximately 8.0849 million Hong Kong dollars to buy back 117...
Bocom Intl: The fifth batch of consumables centralized procurement initiated, focusing on simcere pharma (02096) and other high-elastic symbols under the recovery of the sector.
Bocom Intl believes that there is still further room for recovery in the Mainland pharmaceutical sector in the short term.
[Brokerage Focus] Bocom Intl believes there is still room for further recovery in the pharmaceutical sector in the short term.
Kingwu Finance News | Bocom Intl stated that the fifth batch of consumables for the national procurement has started, and the market for cochlear implants and peripheral interventions may enter a new cycle. In addition, many places have lifted the quantity restrictions on pharmaceuticals used in hospitals, accelerating the entry of pharmaceuticals into hospitals. The bank pointed out that with the inclusion of national procurement, the expected price decrease in cochlear implants may bring incremental market demand, creating market share substitution space for domestic brands. The bank believes that in the short term, there is still room for further recovery in the pharmaceutical sector, with a focus on recommending Simcere Pharma (02096), Hutchmed (China) (00013), CanSino Biologics (02162), and Akeso (09926) due to their rich short-term catalysts and high profit growth.
Is Simcere Pharmaceutical Group (HKG:2096) A Risky Investment?
No Data
No Data